论文部分内容阅读
目的探讨低蛋白饮食联合开同、肾衰宁、羟苯磺酸钙治疗慢性肾衰竭早、中期(血肌酐177～707umol/L)的疗效。方法选择2010年6月至2012年6月于我院就诊的慢性肾衰竭(血肌酐177～707umol/L)患者120例。随机分成两组,治疗组60例,在一般治疗基础上口服开同(0.14～0.18g/(kg·d)、肾衰宁(5g,3次/d)、羟苯磺酸钙(0.5g,3次/d)。对照组在一般治疗的基础上口服开同(0.14～0.18g/(kg·d)、爱西特(1.5g,3次/d)。两组患者均治疗1.5个月,观察症状及体征,两组患者治疗前后各测一次血肌酐(Scr)、肌酐清除率(Ccr)、尿素氮(BUN)、尿酸(UA)、血浆白蛋白,每2周测一次血红蛋白、血钙、血磷,并根据血钙情况调整开同用量。结果治疗1.5个月后两组患者治疗后Scr、BUN、UA均较治疗前有明显下降,差异有统计学意义(P<0.01),治疗组与对照组比较,治疗组下降明显,差异有统计学意义(P<0.05);两组治疗后血浆白蛋白均较治疗前有所上升,差异有统计学意义(P<0.05)。结论低蛋白饮食联合开同、肾衰宁、羟苯磺酸钙治疗慢性肾衰竭早、中期的疗效较好,可改善患者症状,延缓肾功能进展,值得临床推广。
Objective To investigate the efficacy of low protein diet combined with open, kidney failure and calcium dobesilate in the treatment of chronic renal failure in the early and middle stages (serum creatinine 177 ~ 707umol / L). Methods 120 patients with chronic renal failure (serum creatinine 177 ~ 707umol / L) in our hospital from June 2010 to June 2012 were selected. Randomly divided into two groups, the treatment group of 60 patients on the basis of the general treatment of oral open with the same (0.14 ~ 0.18g / (kg · d), kidney decoction (5g, 3 times / d), calcium dobesilate , 3 times / d) .The control group was treated with oral (0.14 ~ 0.18g / (kg · d) and Ai Xit (1.5g, 3 times / d) Month, observe the symptoms and signs, two groups of patients before and after each test of serum creatinine (Scr), creatinine clearance (Ccr), blood urea nitrogen (BUN), uric acid (UA), plasma albumin, hemoglobin measured once every two weeks, (P <0.01) .After treatment for 1.5 months, the levels of Scr, BUN and UA in both groups decreased significantly after treatment compared with before treatment (P <0.01) (P <0.05). Compared with the control group, the treatment group decreased significantly, the difference was statistically significant (P <0.05); both groups plasma albumin after treatment than before treatment increased, the difference was statistically significant (P <0.05). Conclusion Low protein diet combined with open, kidney decoction, calcium dobesilate in the treatment of chronic renal failure early and mid-term better curative effect, can improve the symptoms of patients and delay the progression of renal function, worthy of clinical promotion.